Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary

Abstract Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn’s and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn’s and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn’s and Colitis Canada’s webinar-based knowledge translation platform.

[1]  C. Olson,et al.  Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. , 2021, The New England journal of medicine.

[2]  G. Kaplan,et al.  Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE , 2021, Gastroenterology.

[3]  C. Olson,et al.  Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons , 2021, The New England journal of medicine.

[4]  C. Lees,et al.  Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD , 2021, Gut.

[5]  P. Lochhead,et al.  Inflammatory bowel disease and risk of severe COVID‐19: A nationwide population‐based cohort study in Sweden , 2021, United European gastroenterology journal.

[6]  P. Moayyedi,et al.  COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology , 2021, Journal of the Canadian Association of Gastroenterology.

[7]  M. Parkes,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement , 2021, The Lancet Gastroenterology & Hepatology.

[8]  M. Dubinsky,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.

[9]  M. Kappelman,et al.  Reply , 2021, Gastroenterology.

[10]  Nguyen H. Tran,et al.  Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. , 2020, Lancet.

[11]  Ashutosh Kumar Singh,et al.  Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta‐analysis , 2020, United European gastroenterology journal.

[12]  F. Underwood,et al.  Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. , 2020, The American journal of gastroenterology.

[13]  F. Underwood,et al.  Effect of IBD medications on COVID-19 outcomes: results from an international registry , 2020, Gut.

[14]  M. Kappelman,et al.  Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases , 2020, Clinical Gastroenterology and Hepatology.

[15]  G. Kaplan,et al.  The four epidemiological stages in the global evolution of inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.

[16]  C. Lees,et al.  International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases , 2020, Journal of Crohn's & colitis.

[17]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[18]  F. Krammer.  SARS-CoV-2 vaccines in development , 2020, Nature.

[19]  M. Kappelman,et al.  IBD in the COVID-19 era: the value of international collaboration , 2020, The Lancet Gastroenterology & Hepatology.

[20]  J. Mascola,et al.  An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.

[21]  Walter G. Park,et al.  Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California , 2020, Gut.

[22]  S. Ng,et al.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.

[23]  Philip Smith,et al.  British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic , 2020, Gut.

[24]  Chonggang Xu,et al.  High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[25]  S. Ng,et al.  Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting , 2020, Gastroenterology.

[26]  S. Ng,et al.  Changing Global Epidemiology of Inflammatory Bowel Diseases-Sustaining Healthcare Delivery into the 21st Century. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  G. Kaplan,et al.  Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. , 2019, Gastroenterology.

[28]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: A Scientific Report from the Canadian Gastro-Intestinal Epidemiology Consortium to Crohn’s and Colitis Canada , 2018, Journal of the Canadian Association of Gastroenterology.

[29]  G. Kaplan,et al.  The Impact of Inflammatory Bowel Disease in Canada 2018: IBD in Seniors , 2018, Journal of the Canadian Association of Gastroenterology.

[30]  G. Nguyen,et al.  Transforming Access to Specialist Care for Inflammatory Bowel Disease: The PACE Telemedicine Program , 2018, Journal of the Canadian Association of Gastroenterology.

[31]  G. Kaplan,et al.  Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression , 2018, Gut.

[32]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[33]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[34]  A. Monto,et al.  Detection and control of influenza outbreaks in well-vaccinated nursing home populations. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.